These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 27911951

  • 1. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
    Kotwinski P, Smith G, Cooper J, Sanders J, Ma L, Teis A, Kotwinski D, Mythen M, Pennell DJ, Jones A, Montgomery H, Breast cancer Early disease: Toxicity from Therapy with Epirubicin Regimens–Cardiac Assessment and Risk Evaluation (BETTER-CARE) Study Investigators.
    PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
    [Abstract] [Full Text] [Related]

  • 2. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC, Sandhu NP, Xia H, Cha SS, Pellikka PA, Ye Z, Herrmann J, Villarraga HR.
    BMC Cancer; 2018 Oct 25; 18(1):1037. PubMed ID: 30359235
    [Abstract] [Full Text] [Related]

  • 3. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Kawada M, Hirayama M, Tsuji Y.
    Breast Cancer; 2017 Nov 25; 24(6):774-782. PubMed ID: 28434150
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E, Jug B, Blagus R, Zakotnik B.
    Arq Bras Cardiol; 2016 Jul 25; 107(1):40-7. PubMed ID: 27305108
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.
    Cadeddu C, Piras A, Dessì M, Madeddu C, Mantovani G, Scartozzi M, Hagendorff A, Colonna P, Mercuro G.
    Int J Cardiovasc Imaging; 2017 Feb 25; 33(2):197-207. PubMed ID: 27696298
    [Abstract] [Full Text] [Related]

  • 8. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
    Kimball A, Patil S, Koczwara B, Raman KS, Perry R, Grover S, Selvanayagam J.
    Int J Cardiol; 2018 Jun 15; 261():159-161. PubMed ID: 29576422
    [Abstract] [Full Text] [Related]

  • 9. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF, Mukku RB, Verma S, Liu JE, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.
    Breast Cancer Res Treat; 2017 Nov 15; 166(1):241-247. PubMed ID: 28710537
    [Abstract] [Full Text] [Related]

  • 10. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer.
    Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, Favuzzi AMR.
    Eur Rev Med Pharmacol Sci; 2018 Apr 15; 22(7):2175-2185. PubMed ID: 29687878
    [Abstract] [Full Text] [Related]

  • 11. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J.
    JACC Heart Fail; 2019 Sep 15; 7(9):795-804. PubMed ID: 31401102
    [Abstract] [Full Text] [Related]

  • 12. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW, Ali MT, Tan TC, Cheng KH, Salama L, Hua L, Zeng X, Halpern EF, Taghian A, MacDonald SM, Scherrer-Crosbie M.
    Echocardiography; 2016 Apr 15; 33(4):519-26. PubMed ID: 26992012
    [Abstract] [Full Text] [Related]

  • 13. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.
    J Clin Oncol; 1996 Dec 15; 14(12):3112-20. PubMed ID: 8955656
    [Abstract] [Full Text] [Related]

  • 14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr 15; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 15. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN, Ruthazer R, Miller KD, Parsons SK, Erban JK, O'Neill AM, Demissei B, Sledge G, Wagner L, Ky B, Kent DM.
    Clin Breast Cancer; 2019 Aug 15; 19(4):259-267.e1. PubMed ID: 31175052
    [Abstract] [Full Text] [Related]

  • 16. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK.
    J Natl Cancer Inst; 2008 Aug 06; 100(15):1058-67. PubMed ID: 18664656
    [Abstract] [Full Text] [Related]

  • 17. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Bejarano Hernández S, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M.
    Eur J Cancer; 2015 Nov 06; 51(17):2517-24. PubMed ID: 26321502
    [Abstract] [Full Text] [Related]

  • 18. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
    Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.
    Cardiovasc Toxicol; 2012 Jun 06; 12(2):135-42. PubMed ID: 22189487
    [Abstract] [Full Text] [Related]

  • 19. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA, Oliveira GE, Feijó LA, Garcia MI, Xavier SS, Sousa AS.
    Arq Bras Cardiol; 2018 Feb 06; 110(2):140-150. PubMed ID: 29561992
    [Abstract] [Full Text] [Related]

  • 20. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
    Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA.
    Am J Clin Oncol; 2018 Sep 06; 41(9):909-918. PubMed ID: 28537988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.